Background
The use of pioglitazone, a thiazolidinedione (TZD), may increase the risk of bladder cancer in patients with type 2 diabetes. In this study, we assessed the risk of bladder cancer associated with the use of TZDs and between pioglitazone and rosiglitazone, an alternative TZD.
Methods
We conducted a retrospective cohort study of patients with type 2 diabetes mellitus who initiated treatment with a TZD (n = 18 459 patients) or a sulfonylurea (SU) (n = 41 396 patients) between July 1, 2000, and August 31, 2010, using The Health Improvement Network database in the United Kingdom. Incident cancers were identified for 196 708 person-years of follow-up. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of bladder cancer in the TZD cohort compared with the SU cohort (referent), adjusted for potential confounders. Risk associated with increasing duration of drug exposure was also examined. All statistical tests were two-sided.
Results
We identified 60 incident bladder cancers in the TZD cohort and 137 cancers in the SU cohort. No difference in bladder cancer risk was found between the two cohorts (TZD vs SU, HR = 0.93, 95% CI = 0.68 to 1.29) in analyses that did not account for duration of exposure. However, the risk of bladder cancer was increased among patients with the longest duration of TZD vs SU therapy (≥5 years of use, HR = 3.25, 95% CI = 1.08 to 9.71) and among those with the longest time since initiation of therapy (≥5 years since first use, HR = 2.53, 95% CI = 1.12 to 5.77). Risk of bladder cancer also increased with increasing time since initiation of pioglitazone (P trend < .001) and rosiglitazone (P trend = .006).
Comparison of pioglitazone to rosiglitazone use did not demonstrate difference in cancer risk (P = .49).
Conclusion
Long-term TZD therapy (≥5 years) in patients with type 2 diabetes may be associated with an increased risk of bladder cancer, which may be common to all TZDs.
J Natl Cancer Inst 2012;104:1411-1421
The US Food and Drug Administration (FDA) and other regulatory agencies recently warned prescribers that use of pioglitazone, a thiazolidinedione (TZD), may be associated with an increased risk of bladder cancer (1) . France and Germany removed the drug from their markets although the rest of Europe did not. The TZDs, including pioglitazone and rosiglitazone, are ligands to the peroxisome proliferator-activated receptor gamma (PPAR-γ) and are generally indicated as second-line treatment of type 2 diabetes mellitus. In addition to their role as insulin sensitizers, the TZD PPAR ligands are known to regulate cancer cell growth and differentiation (2) (3) (4) (5) (6) (7) (8) . Thus, it is conceivable that these compounds can influence human cancer risk.
The new safety warning is based on limited clinical data, including two cohort studies using data from the Kaiser Permanente Northern California (KPNC) diabetes registry and data from the French national health insurance information system, and the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study (9) (10) (11) . Interim results from the KPNC study found no association between use of pioglitazone and risk of bladder cancer overall but observed an increased risk with greater than 2 years of therapy (9) . Similar results were reported from the French cohort study (10) . The PROactive study, which was designed to study cardiovascular outcomes, found a non-statistically significant increase in bladder cancer among patients treated with pioglitazone compared with placebo (14 vs 6 cancers, P = .07) (11) . Appropriate application of such safety warnings by physicians requires consideration of the comparative effectiveness and safety of alternative therapies. However, none of the previous studies directly compared the TZDs with sulfonylureas (SUs), the common alternative therapy for type 2 diabetes not adequately controlled with metformin. Furthermore, none assessed the risk associated with other TZDs, such as rosiglitazone.
Diabetes has reached epidemic proportions, affecting 285 million worldwide (12) . The TZDs account for up to 20% of total antidiabetic prescriptions in the United States (13) . Furthermore, restricted access to rosiglitazone because of increased risk of cardiovascular disease has resulted in a substantial increase in pioglitazone use. Given the high prevalence of TZD use, a possible association with bladder cancer can be costly, result in substantial morbidity, and may even result in death. Thus, it is critically important to establish whether or not the TZDs increase the risk of bladder cancer relative to the available alternative therapies, and whether this association differs between pioglitazone and rosiglitazone. In this study, we analyzed the risk of bladder cancer over time between new users of TZDs and SUs, and in a secondary analysis between pioglitazone and rosiglitazone.
Methods

Data Source
The Health Improvement Network (THIN) is a general practitioner electronic medical records database that is generally representative of the broader UK population. Currently, the database contains the electronic medical records of approximately 9.5 million patients.
Data available in THIN include demographic information, medical diagnoses, lifestyle characteristics, and other measurements taken during clinical practice. Medical diagnoses within the database are recorded using Read codes, the standard classification system used in UK primary care settings (14) . THIN also captures all new prescriptions and repeat prescriptions written by the general practitioner as the electronic medical record is used to generate these prescriptions. The accuracy and completeness of THIN data is well documented (15) (16) (17) (18) (19) (20) . Initial audits on contributing practices showed participating practices to record data with sufficient quality to enable them to join the THIN system (21).
Study Design and Population
We used the THIN database to conduct a retrospective cohort study among 403 707 patients with type 2 diabetes mellitus who received a prescription for either a TZD or SU between July 1, 2000, and August 31, 2010. We selected this timeframe because rosiglitazone and pioglitazone have been licensed in the European Union since July 2000. From this source population, we established a study cohort and a comparator cohort that included new users of a TZD or an SU, respectively. A new user was defined as having had at least 6 months of enrollment in THIN without previous prescriptions for either drug (Figure 1 ). Participants with a bladder cancer diagnosis before cohort entry were excluded to avoid misclassification of prevalent cancers as incident cancers. The study protocol was approved by the University of Pennsylvania's Institutional Review Board and the United Kingdom's Scientific Review Committee.
Ascertainment of Exposure
Use of a TZD was defined as receipt of two prescriptions for either rosiglitazone or pioglitazone within 6 months of each other during the study period. The date of the second prescription was taken as the index date. Time since initiation of a TZD was calculated by counting the number of days since the index date. Prescription duration was determined by dividing the prescription quantity by the prescribed number of units per day. To account for gaps in therapy, cumulative duration of exposure was calculated by summing the days' supply for all recorded prescriptions subsequent to the index prescription during the study period.
Identical definitions were used to define exposure to SUs, including first-(acetohexamide, chlorpropamide, tolbutamide, or tolazamide) and second-generation (glipizide, gliquidone, glimepiride, glibenclamide, or gliclazide) drugs. We chose SUs as the comparator drugs because, like TZDs, SUs are generally administered as second-line treatment, hence providing comparable populations of diabetics with respect to duration and severity of disease (22) .
Incident Bladder Cancer and Follow-up
The primary outcome was an incident diagnosis with bladder cancer occurring after the index date. Follow-up started on index date and ended with the earliest of any of the following censoring events: 1) incident diagnosis of bladder cancer, identified by The Read Codes (Version 2); 2) transfer out of practice; 3) death from any cause, identified as a code in the medical records file or the administration file; and 4) end of available data, taken as August 31, 2010 (this date minimizes the chance of surveillance bias as FDA warnings of a possible association between TZDs and bladder cancer were initially issued in September 2010).
Potential Confounding Variables
Data relating to potential confounders were extracted from the database. We considered other diabetes medications (metformin, insulin, meglitinides, incretin mimetics, and acarbose) and variables believed to affect either the risk of bladder cancer (age, sex, smoking, recurrent urinary tract infections, and body mass index [BMI]) or the probability of receiving a TZD (diabetes duration, hemoglobin A1C level, congestive heart failure, myocardial infarction, and renal impairment) as potential confounders. These variables were measured before or within 7 days after the index date, with the exception of cigarette or cigar smoking. Smoking status was measured using data recorded at any time before or during the follow-up period.
Statistical Analysis
We calculated incidence rates of bladder cancer per 100 000 person-years with 95% confidence intervals (CIs) for the study and comparator cohorts. In the primary analysis, once a patient met the definition for exposure to TZDs, they were considered exposed from that point forward even if they discontinued therapy. Patients in the comparator cohort who became exposed to a TZD contributed follow-up time for the comparator cohort until the date upon which they became exposed to a TZD and subsequently entered the TZD cohort. In sensitivity analyses, follow-up time for patients who switched therapy ended at treatment crossover or was carried forward from initial treatment.
We used Cox proportional hazards regression models to calculate relative hazards of bladder cancer in patients exposed to TZDs compared with patients exposed to SUs, adjusted for potential confounders (23) . Because patients could contribute to both the TZD and SU cohorts, we used robust standard error estimates to account for nonindependence (24) . Cox regression models were assembled by retaining covariates associated with bladder cancer having a P value less than .30 or if their inclusion changed the hazard ratio (HR) between TZD exposure and outcome by more than 10% (25) . Full models were subsequently reduced by sequentially deleting variables with model P values greater than .10 to arrive at the final fully adjusted model. The fully adjusted model included age, sex, smoking (ever vs never), and hemoglobin A1C (clinical cut points <7%, 7%-7.9%, 8%-8.9%, 9%-9.9%, and ≥10%). We also tested whether the association of risk of bladder cancer with TZD vs SU use differed by sex.
Cox regression models were also used to assess whether the risk of bladder cancer increased with increasing duration of TZD therapy and time since initiating a TZD, compared with SU therapy. We stratified all exposed follow-up time into discrete intervals of total exposure (<1, 1-2, 2-3, 3-4, 4-5, and ≥5 years) and quantities of cumulative duration of therapy (<1, 1, 2, 3, 4, and ≥5 years). In these analyses, TZD and SU use were categorized in a time-dependent manner. During the follow-up period, each user was categorized according to their duration of therapy or interval of exposure at each point in time. To test for a trend in the Cox regression models, the duration categories were included in the model as a continuous variable, whereas for analysis of discrete duration intervals, the variable was included as a categorical variable. The duration-response analyses were planned a priori given that previous studies found associations among longer term users (>2 years) of pioglitazone (9, 10) .
In a separate cohort of only new users of a TZD (Figure 1) , we compared the risk of bladder cancer between pioglitazone and rosiglitazone. For this comparison, we included patients with and without previous SU use. Patients could only contribute to their baseline cohort; follow-up time continued even if the patient switched from one TZD to another. Survival analysis was conducted using Cox proportional hazards regression models.
A sensitivity analysis was performed to assess the potential impact of an unmeasured confounder on the observed association using the method described by Lin et al. (26) . In this analysis, we re-estimated the association for bladder cancer with TZD vs SU use after adjustment for a hypothetical unmeasured confounder by varying the prevalence of the unmeasured confounder (20%-80%) in the TZD cohort along with the relative hazard for bladder cancer associated with the unmeasured confounder (HR = 2-3).
The proportional hazards assumptions were met for all Cox models. All statistical tests were two-sided and conducted at the 5% statistical significance level using STATA version 11.2 (StataCorp, College Station,TX).
results
Characteristics of Study Participants
The final cohort from the THIN database included 59 855 patients with type 2 diabetes mellitus who were new users of a TZD (study cohort: n = 18 459 patients) or an SU (comparator cohort: n = 41 396 patients). TZD initiators were younger than the comparator SU initiators (median [range] age = 60 [51-69] vs 65 [55-74] years), more likely to have received previous treatment with metformin, insulin, and other diabetes medications, and have longer duration of diabetes (Table 1 ). There were only small differences in sex, smoking, recurrent urinary tract infection, and renal impairment between the TZD and SU cohorts. The median time from index date to the end of follow-up was longer in the TZD cohort compared with the SU cohort (median [range] time = 3.7 [1.9-5.3] years vs 2.4 [1.1-4.7] years) and more than 5 years in 25% of both cohorts. The median duration of exposure was more than 2 years for both cohorts.
When we compared the users of pioglitazone (n = 10 900 pa tients) vs rosiglitazone (n = 17 614 patients), we found that histories of renal impairment and insulin use were more common among 
Association of Risk of Bladder Cancer with TZD vs SU Use
During 196 708 person-years of follow-up, there were 197 incident bladder cancers diagnosed: 60 cancers occurred in the TZD cohort and 137 cancers in the SU cohort ( Table 2 ). The incidence * A retrospective cohort study was conducted within The Health Improvement Network database of patients with type 2 diabetes mellitus to assess risk of bladder cancer among those who initiated treatment with a TZD or an SU between July 1, 2000, and August 31, 2010. Follow-up started on the index date (date of the second prescription) and ended with an incident diagnosis of bladder cancer. TZD = thiazolidinedione; SU = sulfonylurea; IQR = interquartile range, 25th-75th quartile; ACE = angiotensin-converting enzyme; NSAID = nonsteroidal anti-inflammatory drug. † All comparisons have P values less than .01 except recurrent urinary tract infections (P = . 19) . P values were calculated using a two-sided Wilcoxon rank-sum test or χ 2 test. ‡ All comparisons have P values less than .01 except congestive heart failure (P = .82). P values were calculated using a two-sided Wilcoxon rank-sum test or χ 2 test. § Includes 6831 SU initiators who were later exposed to a TZD. ‖ Measured before the index date. ¶ Includes other hypoglycemic agents such as acarbose, meglitinides, and incretin mimetics.
rates of bladder cancer among TZD and SU users were 87.1 (95% CI = 66.5 to 112.1) and 107.2 (95% CI = 89.9 to 126.7), respectively, per 100 000 person-years. There was no difference in the overall bladder cancer risk between the TZD and SU user cohorts in the unadjusted, age-and sex-adjusted, and fully adjusted (adjusted for age, sex, smoking status, and hemoglobin A1C level) models (TZD vs SU, unadjusted HR = 0.81, 95% CI = 0.60 to 1.10; age-and sex-adjusted HR = 1.03, 95% CI = 0.76 to 1.40; and fully adjusted HR = 0.93, 95% CI = 0.68 to 1.29) ( Table 2 ). The association between TZD use and bladder cancer was not confounded by variables such as BMI, recurrent urinary tract infections, diabetes duration, or use of other diabetes drugs, including insulin, nor did this association differ by sex (P interaction = .24). We also tested other drugs that may be associated with diabetes and cancer risk, including angiotensin-converting enzyme inhibitors, statins, aspirin, and nonsteroidal anti-inflammatory drugs (27) (28) (29) (30) . Inclusion of these therapies in the final (ie, fully adjusted) model did not appreciably change the association.
However, when we examined the association between bladder cancer incidence and time since initiation of TZD therapy, the risk of bladder cancer increased with increasing time from TZD exposure (Table 2) . After adjustment for age and sex, an increase in the relative hazard of bladder cancer was observed among TZD users with ≥5 years since initiation of therapy (HR = 3.62, 95% CI = 1.50 to 8.74). After additional adjustment for smoking and hemoglobin A1C concentration, similar increase in risk was observed in the fully adjusted model (HR = 3.42, 95% CI = 1.39 to 8.42) although the test for trend no longer met conventional criteria for statistical significance (age-and sex-adjusted model, P trend = .03; fully adjusted model, P trend = .06). Non-statistically significant increases in bladder cancer risk were seen with increasing duration of TZD therapy (Table 2) . Among SU users, opposite trends with increasing time since initiation and duration of use were noted although these trends were not statistically significant (Table 2) .
When we compared cancer risk between the TZD and SU cohorts over time, we observed a statistically significantly increased risk of bladder cancer among TZD users with ≥5 years since initiation of therapy compared with SU users (TZD vs SU: 3 to <4 years since initiation, HR = 0.94, 95% CI = 0.39 to 2.36; 4 to <5 years since initiation, HR = 0.62, 95% CI = 0.20 to 1.93; ≥5 years since initiation, HR = 2.53, 95% CI = 1.12 to 5.77), and the test for trend was statistically significant (P trend = .03) ( Table 2) . Similarly, increased risks of bladder cancer were observed with increasing duration of TZD compared with SU therapy (3 years of use, HR = 1.50, 95% CI = 0.63 to 3.58; 4 years of use, HR = 0.51, 95% CI = 0.11 to 2.38; ≥5 years of use: HR = 3.25, 95% CI = 1.08 to 9.71) although the test for trend did not reach statistical significance (P trend = .20) ( Table 2) .
In a sensitivity analysis, we further restricted the cohort of new TZD and SU users to patients with type 2 diabetes receiving therapy with metformin at the start of follow-up (n = 42 440 patients).
In this analysis, we obtained similar results to our primary analysis for overall, time since initiation of therapy, and duration of therapy analyses (Supplementary Table 1 , available online). The findings also remained generally unchanged in additional analyses where patients who switched therapy (n = 6831 patients from SU to TZD use, n = 3652 patients from TZD to SU use) were either censored or considered exposed to initial treatment (Supplementary Tables 2  and 3, available online) .
Next we performed a sensitivity analysis to examine the potential for bias from an unmeasured confounder and found that a missing confounder would need to be strongly associated with both TZD exposure and the outcome to appreciably change the results (Supplementary Table 4 , available online). For example, an unmeasured confounder that was twice as prevalent in the TZD cohort compared with the SU cohort and was associated with a two-fold higher bladder cancer incidence would only result in a small reduction in risk of bladder cancer (TZD vs SU: ≥5 years since initiation, fully adjusted HR = 2.53, 95% CI = 1.12 to 5.77 vs HR adjusted for unmeasured confounder = 2.20, 95% CI = 0.97 to 4.99).
Difference in Bladder Cancer Risk Between Pioglitazone and Rosiglitazone Use
In the comparison of pioglitazone and rosiglitazone, a total of 127 new bladder cancers were recorded: 86 cancers among users of rosiglitazone and 41 cancers among users of pioglitazone. The incidence rates of bladder cancer were 123.8 (95% CI = 88.9 to 168.0) and 106.6 (95% CI = 85.3 to 131.6) per 100 000 person-years in the pioglitazone and rosiglitazone cohorts, respectively. Overall, there was no difference in bladder cancer risk between pioglitazone and rosiglitazone users in unadjusted and adjusted models (pioglitazone vs rosiglitazone [referent], unadjusted, HR = 1.16, 95% CI = 0.80 to 1.69; age-and sex-adjusted, HR = 1.15, 95% CI = 0.79 to 1.67; fully adjusted, HR = 1.14, 95% CI = 0.79 to 1.66) ( Table 3 ).
In the duration-response analysis (Table 3) , increases in bladder cancer risk were observed with increasing time since initiation of both pioglitazone (P trend < .001) and rosiglitazone (P trend = .006). The risk of bladder cancer was statistically significantly increased in users of pioglitazone (HR = 6.97, 95% CI = 2.28 to 21.3) and rosiglitazone (HR = 2.91, 95% CI = 1.34 to 6.36) for more than 5 years since initiation of therapy compared with patients who used the drugs for less than 1 year since initiation of therapy. The incidence of bladder cancer also increased with increasing duration of both pioglitazone and rosiglitazone therapy; however, neither trend reached statistical significance (P trend = .13 for both pioglitazone and rosiglitazone).
When we compared the risk of bladder between the pioglitazone and rosiglitazone cohorts, there was no difference in risk associated with pioglitazone use relative to rosiglitazone use (P = .49) with longer time since initiation (P trend = .12) or when accounting for duration of therapy (P trend = .75) ( Table 3) . In this comparison, subjects could only contribute follow-up time to their baseline cohort. In a separate analysis, which allowed subjects to contribute to both cohorts if they switched therapy from rosiglitazone to pioglitazone (n = 4311 patients), similar results were obtained for the overall and duration-response analyses (Supplementary Table 5 , available online).
Discussion
In this large cohort study of 59 855 type 2 diabetes patients included from the THIN database, we compared the risk of bladder cancer associated with TZD use relative to their logical alternative, the SUs. Results from this study suggest that 5 or more years of exposure to TZDs may be associated with a higher incidence of bladder cancer than comparable exposure to SUs. Relative to SU users, we did not observe statistically significantly higher incidence rates of bladder cancer with less than 5 years of TZD therapy. In addition, we observed similar incidence of bladder cancer among patients treated with pioglitazone or rosiglitazone regardless of the duration of exposure. * A retrospective cohort study was conducted within The Health Improvement Network database of patients with type 2 diabetes mellitus who initiated treatment with a TZD or SU. Cox regression models were used to estimate relative hazards for bladder cancer in the TZD cohort relative to the SU cohort, and with increasing time since initiation of TZD vs SU therapy, and increasing duration of TZD vs SU therapy. IR = incidence rate; HR = hazard ratio; CI = confidence interval; PYS = person-years; SU = sulfonylurea; TZD = thiazolidinedione; -= not applicable. † Adjusted for age (<60, 60-69, ≥70 years), sex, smoking (ever vs never), and hemoglobin A1C level (<7%, 7%-7.9%, 8%-8.9%, 9%-9.9%, and ≥10%). ‡ P values were calculated using a two-sided test for trend in the Cox regression models. The duration categories were included in the model as a continuous variable, whereas for analysis of discrete duration intervals, the variable was included as a categorical variable.
This potential association was first reported in preclinical studies of rats treated with pioglitazone (31) and later in the PROactive trial (11) . In PROactive, most bladder cancer cases occurred within 1 year of pioglitazone therapy and were, therefore, less likely to be biologically related. However, the mechanism by which TZDs induce carcinogenesis is not known. If they function as a cancer initiator, then de novo tumor progression typically requires decades. If as a promoter, then cancer risk might be apparent in a shorter period * A retrospective cohort study was conducted within The Health Improvement Network database of patients with type 2 diabetes mellitus who initiated treatment with PIO or ROSI. Cox regression models were used to estimate relative hazards for bladder cancer in the PIO cohort relative to the ROSI cohort, and with increasing time since initiation of PIO vs ROSI therapy, and increasing duration of PIO vs ROSI therapy. All statistical tests were two-sided. IR = incidence rate; HR = hazard ratio; CI = confidence interval; PYS = person-years; PIO = pioglitazone; ROSI = rosiglitazone; -= not applicable. † Adjusted for age (<60, 60-69, ≥70 years), sex, smoking (ever vs never), history of myocardial infarction, and past sulfonylurea use. ‡ P values were calculated using a two-sided test for trend in the Cox regression models. The duration categories were included in the model as a continuous variable, whereas for analysis of discrete duration intervals, the variable was included as a categorical variable.
of time. Given that patients with diabetes may have an increased risk of bladder cancer at baseline, it is plausible that the TZDs may accelerate an already nascent process in a high-risk group (32) (33) (34) (35) . More recent data to address these risks directly in humans have emerged, including an interim analysis from a KPNC cohort study, and retrospective French and Taiwanese cohort studies. Results from the KPNC study showed an increase in the relative hazards of bladder cancer with increasing duration of pioglitazone therapy relative to no exposure to pioglitazone (HR = 0.8, 95% CI = 0.5 to 1.2 for <12 months of use, HR = 1.3, 95% CI = 0.9 to 2.0 for 12-24 months, HR = 1.3, 95% CI = 0.8 to 2.2 for 24-36 months, HR = 1.5, 95% CI = 0.8 to 2.2 for 36-48 months, and HR = 1.7, 95% CI = 1.1 to 2.9 for >48 months) (9) . The French study found similar hazards of bladder cancer among pioglitazone users compared with nonusers (HR = 1.34, 95% CI = 1.02 to 1.75 for 12-23 months of use, and HR = 1.36, 95% CI = 1.04 to 1.79 for >24 months) after adjustment for age, sex, and other diabetes drugs (10) . The Taiwanese study reported a 30% non-statistically significantly increase in overall risk although only 10 bladder cancers were identified among pioglitazone-exposed patients (36) . These studies did not distinguish whether the observed associations were unique to pioglitazone or common to all TZDs. Furthermore, the studies did not use a single comparator group.
In our study, when increasing duration of TZD treatment was compared to treatment with its common alternative-the SUs, we also observed the greatest risk in those who received treatment for the longest duration and those who started treatment longest ago. The reproducibility of the findings from the US and French studies, and now using UK data, provides support for the hypothesis that long-term treatment with the TZDs may be associated with an increased risk of bladder cancer relative to the common alternative therapy, an effect that does not seem unique to pioglitazone.
There are several important strengths of this study. THIN contains complete and accurate prescription and diagnostic information, on which our exposure and outcome ascertainment was based. The validity of diagnostic codes for cancer in a related database (General Practice Research Database) for which there is some overlap in practices with THIN and that uses the same electronic medical record software for data collection was recently documented (37) . Furthermore, in a recent study, recorded cancer incidence in THIN was found to be comparable to that expected in the United Kingdom based on national cancer registry data (38) . The Office for National Statistics estimates bladder cancer incidence in the United Kingdom to be 73 per 100 000 person-years during the years 2006-2008 (39) . In comparison, the rates in this cohort were slightly higher than that reported in UK cancer registry data, which is consistent with previous studies demonstrating an increased risk of bladder cancer among patients with type 2 diabetes mellitus (32) (33) (34) (35) .
Compared with previous studies (9, 10, 36) addressing the association of TZD use and bladder cancer, there are several unique features of this study. We used a new user design, comparing TZDs to the most common alternative therapy for patients with inadequate glucose control with metformin alone. The new user design minimizes the risk of bias from including treatment groups with different durations of previous therapy (40) . It also assigns a chronological reference point for each cohort member to allow for an accurate assessment of duration effects, a critical analysis in this study. Duration of TZD exposure was measured as time since first exposure and cumulative duration of exposure, as both factors may relate to risk for carcinogenesis.
Another unique aspect of this study is the direct comparison of bladder cancer risk between pioglitazone and rosiglitazone users. We hypothesized that if pioglitazone use is associated with an increased incidence of bladder cancer, the association may be a class effect (ie, common to all drugs in the class). A class effect is biologically plausible as both agents have high affinity for PPAR-γ, have similar mechanisms of action, and share associations with several adverse events (41) (42) (43) . Findings from this analysis demonstrate similar increases in cancer risk for both pioglitazone and rosiglitazone use with increasing time since initiation and duration of therapy, suggesting that this association is not specific to pioglitazone alone. When we directly compared pioglitazone exposure to rosiglitazone exposure over increasing time since initiation and duration of use, we did not observe differences in cancer risk, further supporting the hypothesis that the association of bladder cancer with TZDs may be a class effect. Similar results were obtained when we allowed rosiglitazone initiators to contribute follow-up time to the pioglitazone cohort had they switched therapy to pioglitazone (Supplementary Table 5 , available online).
We observed a large number of bladder cancers among individuals who completed less than a year of therapy with pioglitazone (n = 17) or rosiglitazone (n = 30) ( Table 3 ). The majority of these cancers occurred >2 years from initiating therapy (data not shown), perhaps suggesting that patients who discontinued therapy early were in some way predisposed to develop bladder cancer at a later time. Interestingly, the same pattern was observed among SU-treated patients. Because we used less than 1 year since initiation of therapy as our reference category, this appears to have contributed to the somewhat lower hazard ratios in our duration of therapy analysis than in our time since initiation analysis among the TZD users. In contrast, when compared to SU users, the hazard ratio for ≥5 years of therapy was slightly stronger than that for 5 years since initiation of therapy, both being statistically significantly elevated.
There are several potential limitations of this study. It is possible that we misclassified some unexposed patients as exposed; however, we required patients to have filled two prescriptions within a 6-month period to assure the cohort included people who actually took the medications. Because nearly 20% of subjects in the study (ie, TZD) cohort and 17% in the comparator (ie, SU) cohort switched from one therapy to the other, we considered the potential for bias from treatment crossover in sensitivity analyses. We observed similar results whether we censored subjects at treatment switch (Supplementary Table 2 , available online) or carried initial treatment forward (Supplementary Table 3 , available online).
As with all observational studies that examine the effects of medications, there is the potential for confounding by indication. A possible association between diabetes and bladder cancer has been previously described; therefore, this study may be subject to confounding by indication on the basis of group differences in the severity and duration of diabetes between the TZD and SU cohorts. To minimize these differences, we selected a comparable reference group of new users of SUs, the commonly used alternative indicated for the second-line treatment of diabetes (22) .
Although TZD users had a longer duration of diabetes, possibly because of inclusion of some previous SU users, diabetes duration was not observed to be a confounder in the association between TZD use and bladder cancer. Were there important confounding by indication, we would have expected to see an increase in the incidence of bladder cancer shortly after the initiation of TZD therapy, a time period that seems biologically implausible to attribute new bladder cancer diagnoses to the medication exposure. Yet we found no evidence of an association in the first year after initial exposure (HR = 0.99, 95% CI = 0.52 to 1.89) ( Table 2) . We also would have expected to find a duration-response relationship with SU use, which was absent. Furthermore, when we conducted a separate analysis of truly comparable second-line therapy where metformin use at baseline was required, our results were nearly identical to the primary analysis. Thus, substantial bias from confounding by indication seems unlikely to have impacted our results.
We have not adjusted for multiple comparisons in these analyses. As such, some statistical associations might be expected by chance alone. However, given that the time since initiation and duration of therapy analyses appear to be generally correlated, and that all the analyses in the paper were targeted toward one a priori hypothesis, and the statistical robustness of many of our findings, correction for multiple comparisons would be overly conservative.
Our cohorts also had incomplete or missing data on several variables. Race and occupational exposure are factors known to be associated with bladder cancer and are missing in THIN database. This may result in residual confounding. Sensitivity analyses to evaluate the potential effect of unmeasured confounders determined that an omitted confounder would have to be both highly prevalent (≥80% prevalence) and strongly associated with bladder cancer (HR approximately 3) in the TZD cohort to substantially reduce our effect size (Supplementary Table 4 , available online). However, relatively few people have occupational associations that increase the risk of bladder cancer, and the association between occupational exposures and bladder cancer incidence are weak (44) . Similarly, black race is uncommon in the United Kingdom (<5%) (45) . Furthermore, Lewis et al. (9) did not observe these to be confounders in their study of pioglitazone and bladder cancer, and others have also found that use of TZDs does not differ by race and/or ethnicity (9, 46) . Thus, it is extremely unlikely for variables such as race and occupation to be major confounders in our study. Data on hemoglobin A1C were missing in less than 2% and 10% of TZD and SU cohort members, respectively. Although hemoglobin A1C was associated with bladder cancer risk, it was not a confounder of the TZD-bladder cancer association; thus, we restricted our analysis to those subjects with A1C data recorded.
Finally, cancer stage is unavailable in the THIN database. In the study by Lewis et al. (9) , there were proportionately more early-stage (in situ and localized) cancers in users of pioglitazone. If TZD users underwent greater surveillance for bladder cancer, such as with more frequent testing for hematuria, then TZD-treated patients might be more frequently diagnosed with early-stage cancers compared to SU users. Because our study ended prior to public warnings regarding the potential TZD-bladder cancer association, differential surveillance in response to public warnings is unlikely. Likewise, recommendations for screening for proteinuria among patients with diabetes do not distinguish between patients receiving SU or TZD therapy. Finally, further adjustment for conditions that may prompt increased testing, such as histories of bladder infections and renal impairment, did not change the risk estimates in our primary analysis. Each of these argues against differential surveillance for bladder cancer between patients treated with TZDs and SUs. One could indirectly assess for a stage shift by looking at bladder cancer-related mortality among those diagnosed with bladder cancer. Unfortunately, cause of death is often difficult to establish, and as such we have not attempted to define bladder cancer-specific mortality rates. Thus, we cannot completely rule out the possibility of increased surveillance for bladder cancer among the TZD-treated patients.
In the United States, rosiglitazone use is now extremely limited. However, pioglitazone is the ninth leading prescription drug (47) with an estimated 15 million annual prescriptions written in 2009 (N. D. Shah, personal communication). Given the highly prevalent use of pioglitazone, an association with bladder cancer would have considerable public health implications. Our study strengthens accumulating evidence that chronic TZD therapy is associated with an increased incidence of bladder cancer, with the highest risk seen among those with the longest duration of exposure. Results from this study extend the findings of recent US and French cohorts by directly comparing TZDs to SUs. However, these results need to be placed into context of other potential benefits and harms of TZDs and SUs. For example, although pioglitazone use has also been associated with fluid retention, congestive heart failure, and bone fractures (41, 42) , there is evidence to suggest that treatment with pioglitazone reduces the need for insulin and improves cardiovascular outcome in patients with diabetes who are at high cardiovascular risk (11) . The SUs associated with a relatively faster glucose lowering effect carry risks of weight gain and life-threatening hypoglycemia (48) .
In summary, among this large cohort of patients with type 2 diabetes mellitus, we observed higher incidence rates of bladder cancer with ≥5 years of exposure to TZDs but not among those with shorter duration of exposure to TZDs. The data from our study may help government regulators, prescribers, and patients to assess the risk-benefit relationship when choosing between these widely used oral hypoglycemic agents. Currently, there is insufficient evidence that bladder cancer screening in asymptomatic adults improves health outcomes (49) . However, physicians should remain vigilant to evaluate hematuria and urinary symptoms when present. 
